Decoy Receptor

Decoy Receptor designates naturally occurring or engineered receptors that bind ligands without triggering downstream signalling, effectively sequestering or neutralising these molecules and preventing their interaction with functional signalling receptors. These molecular traps regulate biological processes by competing with authentic receptors for ligand binding, modulating pathway activity through ligand availability rather than signal transduction. Decoy receptors exist naturally as soluble proteins or membrane-bound forms lacking intracellular signalling domains, serving important physiological roles in fine-tuning immune responses, angiogenesis, and other processes.

The biopharmaceutical industry has developed therapeutic decoy receptors as innovative biologics addressing diverse diseases. Aflibercept exemplifies successful decoy receptor therapeutics, comprising VEGF receptor domains fused to antibody Fc regions, binding and neutralising vascular endothelial growth factor to treat neovascular eye diseases and certain cancers. This approach offers advantages including high binding affinity from optimised receptor domains, extended circulation through Fc fusion, and broad ligand neutralisation capturing multiple related factors. Development requires identifying appropriate receptor components providing desired specificity and affinity, optimising fusion architectures balancing pharmacokinetics with functional activity, and characterising binding properties and neutralisation capacity. As understanding of cytokine networks, growth factor signalling, and immune regulation deepens, decoy receptor approaches continue expanding with novel targets and optimised designs addressing therapeutic areas from autoimmune diseases to cancer.